Navigation Links
CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinson's Disease Motor Symptoms
Date:12/19/2007

CLEVELAND, Dec. 19 /PRNewswire/ -- Cleveland Medical Devices Inc. (CleveMed) announced that it has been awarded $1.5 million in NIH SBIR Phase II Continuation funding from the National Institute of Neurological Disorders and Stroke (NINDS). The grant will fund further development and clinical validation of Kinesia(TM), a quantitative motor assessment system for evaluating Parkinson's disease symptom severity. The initiative includes a large multi-center clinical trial with University Hospitals of Cleveland, the University of Cincinnati, and The Clinical Neuroscience Center in Detroit, Michigan as the participating centers. The trial will aid in development of Kinesia for continuous symptom monitoring in patients' homes, as well as further validate the correlation between the device and the Unified Parkinson's Disease Rating Scale (UPDRS).

Kinesia is a compact lightweight system worn on a patient's wrist and hand. The device monitors three-dimensional motion and electrical muscle activity (EMG) to objectively quantify the severity of Parkinson's disease symptoms, such as tremor, bradykinesia (slowed movements) and dyskinesias (wild, involuntary movements). Patients follow on screen video instruction while data is wirelessly transmitted to a computer to enhance user safety and comfort.

"Objective quantification of Parkinson's disease symptoms such as tremor, bradykinesia, and dyskinesias is important in light of new pharmaceutical trials and novel therapies such as deep brain stimulation," said Dr. Alberto Espay, Neurologist at the University of Cincinnati Movement Disorders Center. "The technology should prove useful for quantifying symptoms in-clinic and tracking symptom fluctuation patterns at patients' homes to more effectively modulate treatments, ultimately improving quality of life for individuals with Parkinson's disease."

A previous clinical study involving 60 Parkinson's patients showed good correlation between Kinesia and the UPD
'/>"/>

SOURCE CleveMed
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Inc. (Nasdaq: ENMD ), today announced the ... sales of Thalomid® during the third quarter compared ... In addition, the Company anticipates a decrease in ... The difference in estimated and actual revenues ... the fourth quarter financial results. ,, (Logo: ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
(Date:12/11/2009)... have observed the "hot electron" effect in a solar ... elusive charges using ultra-thin solar cells, opening a potential ... in the current online edition of Applied Physics ... cells, it generates free electrons in a range of ... the electrons must reach the bottom of the conduction ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...
Breaking Biology Technology:EntreMed Reports Receipt of Third Quarter Royalty Payment 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Elusive 'hot' electrons captured in ultra-thin solar cells 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... increased 40.8% to $11.6 million ... Net Income increased 118.8% to $2.5 ... China Medicine,Corporation (OTC Bulletin Board: CHME) ("China Medicine" ... prescription and over-the-counter,pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional ...
... Tate & Lyle Bio Products today announced that its breakthrough ... a natural ingredient by ECOCERT®, one of the leading international ... ... Loudon, TN August 13, 2008 –- http://www.duponttateandlyle.com/ [DuPont ...
... from the Defense Threat Reduction Agency Will Fund the, Advanced Development ... ... Countermeasure -, CHICAGO, Aug. 13 Advanced Life Sciences,Holdings, ... Agency (DTRA) of the U.S. Department of Defense has awarded the,Company ...
Other Biology Technology:China Medicine Announces Strong Second Quarter 2008 Results 2China Medicine Announces Strong Second Quarter 2008 Results 3China Medicine Announces Strong Second Quarter 2008 Results 4China Medicine Announces Strong Second Quarter 2008 Results 5China Medicine Announces Strong Second Quarter 2008 Results 6China Medicine Announces Strong Second Quarter 2008 Results 7China Medicine Announces Strong Second Quarter 2008 Results 8China Medicine Announces Strong Second Quarter 2008 Results 9China Medicine Announces Strong Second Quarter 2008 Results 10China Medicine Announces Strong Second Quarter 2008 Results 11Zemea Propanediol Approved as a Natural Ingredient by ECOCERT 2Zemea Propanediol Approved as a Natural Ingredient by ECOCERT 3Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million 2Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million 3Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million 4
(Date:12/14/2009)... be transmitted by sneezing, touching, or for Tasmanian ... habit that may have driven the dinosaurs to extinction ... Upcroft, a member of f1000 Biology, highlights the ,paleobiological ... PLoS One. This led them to deduce that a ... bones seen in many tyrannosaurid fossils. , The parasite,s ...
(Date:12/14/2009)... defining feature of humans. That,s until examples of tool use ... array of other mammals. Now, a report in the December ... publication, adds an octopus to the growing list of tool ... trick that the researchers call stilt walking. In it, the ... makes its eight arms rigid, and raises the whole assembly ...
(Date:12/13/2009)... about how a popular class of drugs used ... previously hidden components of chemical communication in the ... the illness, people with schizophrenia also struggle to ... order, difficulties that interfere with their ability to ... Schroeder, a student in the medical scientist training ...
Breaking Biology News(10 mins):Tool use in an invertebrate: The coconut-carrying octopus 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 1NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 2NYU Langone Medical Center awarded NIH grants totaling 241 560 000 8981 3Give an Hour 28TM 29s Volunteer Mental Health Professionals Provide More Than 241 4 Million in Services to Iraq and Afghanistan Veterans Families a 49927 1Give an Hour 28TM 29s Volunteer Mental Health Professionals Provide More Than 241 4 Million in Services to Iraq and Afghanistan Veterans Families a 49927 2Give an Hour 28TM 29s Volunteer Mental Health Professionals Provide More Than 241 4 Million in Services to Iraq and Afghanistan Veterans Families a 49927 3PHT Names VP to Lead Sales of A Claim Payment Solution for Doctors Hospitals 49924 1PHT Names VP to Lead Sales of A Claim Payment Solution for Doctors Hospitals 49924 2
... new antimicrobial approach can kill bacteria in laboratory experiments ... a key bacterial nutrient, according to research led by ... at the UW, the University of Iowa, and the ... 2 issue of the Journal of Clinical Investigation. ...
... bacterial composition of the oral cavity even in low doses. ... needed to counteract the production of acid between the teeth, ... defend at Umeå University in Sweden on February 23. , ... of the sugar xylose, or wood sugar. Xylitol occurs ...
... light are providing insight into the complexities of the sense ... how the human brain works. , Investigators at Duke University ... a strain of mice whose olfactory brain cells "fire" when ... cells a gene naturally present in green algae that "turns ...
Other Biology News:Trojan horse strategy defeats drug-resistant bacteria 2Xylitol reduces risk of cavities 2Common algae helps illustrate mammalian brain electrical circuitry 2Common algae helps illustrate mammalian brain electrical circuitry 3
Rabbit anti-T-box 6...
TNF-R2 (L-20)...
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
... SizeSep 400 Spun Columns, 10. *SizeSep ... cDNAs > 400 base pairs in length. ... Sepharose CL-4B and pre-equilibrated in distilled water containing ... smaller than ~ 400 base pairs. ...
Biology Products: